clinical trialBiotech

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors (NCT07277413)

updatedDate Venue ClinicalTrials.gov

Source-permitted summary

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors | Phase: PHASE1 | Conditions: NSCLC Adenocarcinoma, Gastroesophageal Cancer (GC), Gastric Adenocarcinoma

SourceClinicalTrials.gov

Verified by AISci

Public source attached

Source status for this paper in the current AISci reviewed snapshot.

Primary source
ClinicalTrials.gov
Correction status
none
Evidence coverage
1 sources / 1 publishers
Last metadata check
Jul 19, 2026
Open primary source

AI Reading Notes

Core signal

Structured notes generated from source-linked AISci metadata. Treat them as a reading aid, not a substitute for the paper.

Core signal
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors | Phase: PHASE1 | Conditions: NSCLC Adenocarcinoma, Gastroesophageal Cancer (GC), Gastric Adenocarcinoma
Field context
Protein and Drug Design
People and labs
Not stated in the reviewed source.
Why it matters
Clinical trial registry updates are translation signals, not commercialization claims by themselves.
Limits to check
ClinicalTrials.gov status does not prove product approval, licensing, revenue, or market adoption.

Publication facts

Type
clinical trialSourceClinicalTrials.gov
Venue
ClinicalTrials.govSourceClinicalTrials.gov

External IDs

Author order

No reviewed author edge is attached to this output.

Organizations

No source-confirmed author affiliation is attached.

Related events

Topics

Relationship evidence

Timeline

  1. clinical trialA Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors